biostudies-literatureUnknown34Lin DIMesonephric carcinoma is a rare cancer that most often arises within the cervix, and less frequently, in the ovary and endometrium. A retrospective search of our CLIA-certified and CAP-accredited reference molecular laboratory database (Foundation Medicine, Inc.) identified 20 mesonephric or mesonephric-like, cervical (n = 10), endometrial (n = 5), ovarian (n = 4) or peri-bladder (n = 1) carcinomas that had undergone comprehensive genomic profiling via next generation sequencing. Activating <i>KRAS</i> mutations were present in 90%, 18 of 20 cases, including G12V (n = 7), G12D (n = 6), G12A (n = 3) and G12C (n = 2). Other recurrent alterations were identified in <i>ARID1A</i> (25%), <i>PIK3CA</i> (20%), <i>CTNNB1</i> (15%), <i>TP53</i> (10%), <i>MLL2</i> (10%) and <i>CDKN2A</i> (10%). One Gynecologic oncology reports100652https://www.ebi.ac.uk/biostudies/studies/S-EPMC7529833biostudies-literatureMolecular profiling of mesonephric and mesonephric-like carcinomas of cervical, endometrial and ovarian origin.PMC7529833Killian JKShah NHemmerich ASeverson EAHuang RSPElvin JAHaberberger JTse JYEdgerly CRamkissoon SHLin DIVergilio JARoss JSfalseMolecular profiling of mesonephric and mesonephric-like carcinomas of cervical, endometrial and ovarian origin.Mesonephric carcinoma is a rare cancer that most often arises within the cervix, and less frequently, in the ovary and endometrium. A retrospective search of our CLIA-certified and CAP-accredited reference molecular laboratory database (Foundation Medicine, Inc.) identified 20 mesonephric or mesonephric-like, cervical (n = 10), endometrial (n = 5), ovarian (n = 4) or peri-bladder (n = 1) carcinomas that had undergone comprehensive genomic profiling via next generation sequencing. Activating <i>KRAS</i> mutations were present in 90%, 18 of 20 cases, including G12V (n = 7), G12D (n = 6), G12A (n = 3) and G12C (n = 2). Other recurrent alterations were identified in <i>ARID1A</i> (25%), <i>PIK3CA</i> (20%), <i>CTNNB1</i> (15%), <i>TP53</i> (10%), <i>MLL2</i> (10%) and <i>CDKN2A</i> (10%). One 2020-01-01T00:00:00Z2020 Nov2025-04-18T19:38:24.412Z2020-11-07T09:59:44ZS-EPMC75298333302480710.1016/j.gore.2020.100652